Roivant Sciences Ltd. (ROIV)

Environment story

Roivant discloses no quantified Scope 1, 2, or 3 emissions data, net-zero targets, or decarbonization initiatives in available filings. As a clinical-stage biopharmaceutical company without commercial operations or manufacturing facilities, direct operational environmental footprint is minimal. However, the company's silence on supply-chain emissions (particularly for contract manufacturing and clinical trial sites in Asia), lack of renewable energy commitments, and absence of published environmental targets collectively suggest low environmental governance maturity. No greenwashing detected (company makes no environmental claims to contradict), but material disclosure gaps prevent higher scoring. The company faces tariff and supply-chain disruption risks related to Asian manufacturing dependencies.

Social story

Roivant discloses limited social metrics. The 10-K does not provide CEO-to-median-worker pay ratios, workforce diversity percentages, or union status. The company reports no major strikes, labor disputes, or documented union-suppression activities within the 24-month window. Executive compensation is disclosed (Senior Executive Compensation Program with multi-year equity and cash awards to Matthew Gline, Mayukh Sukhatme, Eric Venker, and Frank Torti), but baseline worker compensation data is absent. No supply-chain human-rights audits or conflict-minerals policies are mentioned. Immunovant and other Vants operate with independent management teams, which may create employment stability risks if key leadership departs. No evidence of formal diversity programs, civil-rights audits, or supplier-diversity initiatives in provided documents.

Governance story

Roivant operates a complex Vant structure with parent company and multiple subsidiaries (Immunovant, Priovant, Pulmovant, Genevant, others), some publicly traded. Board independence percentage not disclosed in available filings. No evidence of dual-class share structures with unequal voting rights for parent company (Roivant Sciences Ltd.). No documented active lobbying opposing climate or consumer-protection regulation. No material antitrust, consumer-safety, or financial-fraud proceedings disclosed. However, governance structure creates operational complexity: (1) Roivant officers serve dual roles on Vant boards, creating potential fiduciary conflicts; (2) equity dilution risk from Vant equity plans; (3) loss of control risk if ownership in Vants falls below majority (e.g., future dilution at Immunovant). The Immunovant subsidiary is publicly traded, limiting Roivant's operational control. No shareholder activism or governance controversies documented in provided source materials.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Roivant Sciences Ltd.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Roivant Sciences Ltd. in the app for interactive charts and portfolio building.

More in Healthcare